A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed 18 enrolled CStone Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open label, dose escalation \& expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006.

Timeline

Start: 2018-06-14
Primary completion: 2020-06-18
Completion: 2020-06-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CS3006	Unknown	—	Oral

A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors

Summary

Timeline

Drugs

Indications